Evidence for neuroprotection by the fenamate NSAID, mefenamic acid

Neurochemistry International

Volumn 55, Issue 7, 2009, Pages 683-688

  Khansari, Parto S ^a   Halliwell, Robert F ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Fenamates; Mefenamic acid; Middle cerebral artery occlusion; Neuroprotection; NSAID

Indexed keywords

DIZOCILPINE; GLUTAMIC ACID; LACTATE DEHYDROGENASE; MEFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN EDEMA; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EVOKED RESPONSE; HIPPOCAMPUS; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN EDEMA; CELL DEATH; GLUTAMIC ACID; HIPPOCAMPUS; INFARCTION, MIDDLE CEREBRAL ARTERY; ISCHEMIC ATTACK, TRANSIENT; MALE; MEFENAMIC ACID; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; STROKE;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 69349094657     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.06.014     Document Type: Article

References (44)

1. Asanuma M., Nishibayashi-Asanuma S., Miyazaki I., Kohno M., and Ogawa N. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J. Neurochem. 76 (2001) 1895-1904
2. Bannwarth B., Netter P., Pourel J., Royer R.J., and Gaucher A. Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs in the cerebrospinal fluid. Biomed. Pharmacother. 43 (1989) 121-126
3. Beresford I.J., Parsons A.A., and Hunter A.J. Treatments for stroke. Expert. Opin. Emerg. Drugs 8 (2003) 103-122
4. Brewer G.J., Torricelli J.R., Evege E.K., and Price P.J. Optimized survival of hippocampal neurons in B-27 supplemented NEUROBASAL™. A new serum-free medium combination. J. Neurosci. Res. 35 (1993) 567-576
5. Candelario-Jalil E., and Fiebich B.L. Cycloxygenase inhibition in ischemic brain injury. Curr. Pharm. Des. 14 (2008) 1401-1418
6. Chen Q., Olney J.W., Lukasiewicz P.D., Almli T., and Romano C. Fenamates protect neurons against ischemic and excitotoxic injury in chick embryo retina. Neurosci. Lett. 242 (1998) 163-166
7. Cheng Y.D., Al-Khoury L., and Zivin J.A. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRX 1 (2004) 36-45
8. Coyne L., Su J., Patten D., and Halliwell R.F. Characterization of the interaction between fenamates and hippocampal neuron GABA(A) receptors. Neurochem. Int. 51 (2007) 440-446
9. Cryer B., and Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used non-steroidal anti-inflammatory drugs. Am. J. Med. 104 (1998) 413-421
10. Davson H. Physiology of the CSF and Blood Brain Barrier (1996), CRC Press, Boca Raton, FL
11. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc. Dis. 15 (2003) 222-229
12. Fisher M., Dávalos A., Rogalewski A., Schneider A., Ringelstein E.B., and Schäbitz W.R. Toward a multimodal neuroprotective treatment of stroke. Stroke 37 (2006) 1129-1136
13. Flower R., Gryglewski R., Herbaczyńska-Cedro K., and Vane J.R. Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat. N. Biol. 238 (1972) 104-196
14. Gladstone D.J., Black S.E., and Hakim A.M. Toward wisdom from failure Lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33 (2002) 2123-2136
15. Green A.R. Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. Clin. Exp. Pharmacol. Physiol. 29 (2002) 1030-1034
16. Görgülü A., Kinş T., Cobanoglu S., Unal F., Izgi N.I., Yanik B., and Küçük M. Reduction of edema and infarction by Memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat. Acta Neurochir. (Wien.) 142 (2000) 1287-1292
17. Halliwell R.F., Thomas P., Patten D., James C.H., Martinez-Torres A., Miledi R., and Smart T.G. Subunit-selective modulation of GABAA receptors by the non-steroidal anti-inflammatory agent, mefenamic acid. Eur. J. Neurosci. 11 (1999) 2897-2905
18. Hammerman C., and Kaplan M. Ischemia and reperfusion injury. The ultimate pathophysiologic paradox. Clin. Perinatol. 25 (1998) 757-777
19. Houin G., Tremblay D., Bree F., Dufour A., Ledudal P., and Tillement J.P. The pharmacokinetics and availability of nuflumic acid in humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 21 (1983) 130-134
20. Ikonomidou-Turski C., Cavalheiro E.A., Turski L., Bortolotto Z.A., Kleinrok Z., CalderazzoFilho L.S., and Turski W.A. Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by pilocarpine in rats. Brain Res. 462 (1988) 275-285
21. Jian Liu K., and Rosenberg G.A. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic. Biol. Med. 39 (2005) 71-80
22. Joo Y., Kim H.S., Woo R.S., Park C.H., Shin K.Y., Lee J.P., Chang K.A., Kim S., and Suh Y.H. Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models. Mol. Pharmacol. 69 (2006) 76-84
23. Kawaguchi M., Furuya H., and Patel P. Neuroprotective effects of anesthetic agents. J. Anesth. 19 (2005) 150-156
24. Kelly J.J., and Auer R.N. Mefenamate, an agent that fails to attenuate experimental cerebral infarction. Can. J. Neurol. Sci. 30 (2003) 259-262
25. Lazovic J., Basu A., Lin H.W., Rothstein R.P., Krady J.K., Smith M.B., and Levison S.W. Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection. Stroke 36 (2005) 2226-2231
26. Lee Y.T., and Wang Q. Inhibition of hKv2.1, a major human neuronal voltage-gated Kq channel, by meclofenamic acid. Eur. J. Pharmacol. 378 (1999) 349-356
27. Lerma J., and Martin del Rio R. Chloride transport blockers prevent N-methyl-d-aspartate receptor-channel complex activation. Mol. Pharmacol. 41 (1992) 217-222
28. Lo E.H., Dalkara T., and Moskowitz M.A. Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci. 4 (2003) 399-415
29. Lyden P., and Wahlgren N.G. Mechanisms of Action of Neuroprotectants in Stroke. J. Stroke Cerebrovasc. Dis. 9 (2000) 9-14
30. Maiese K. From the bench to the bedside: the molecular management of cerebal ischemia. Clin. Neuropharmacol. 21 (1998) 1-7
31. Matsuo Y., Mihara S.I., Ninomiya M., and Fujimoto M. Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. Stroke 32 (2001) 2143-2148
32. Muir K.W. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke 33 (2002) 1545-1550
33. Partridge L.D., Muller T.H., and Swandulla D. Calcium-activated non-selective channels in the nervous system. Brain Res. Brain Res. Rev. 19 (1994) 319-325
34. Partridge L.D., and Valenzuela C.F. Block of hippocampal CAN channels by flufenamate. Brain Res. 867 (2000) 143-148
35. Peretz A., Degani N., Nachman R., Uziyel Y., Gibor G., Shabat D., and Attali B. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol. Pharmacol. 67 (2005) 1053-1066
36. Ramos C.M., Pou S., and Rosen G.M. Effect of anti-inflammatory drugs on myeloperoxidase-dependent hydroxyl radical generation by human neutrophils. Biochem. Pharmacol. 49 (1995) 1079-1084
37. Santos M.S., Moreno A.J., and Carvalho A.P. Relationships between ATP depletion, membrane potential, and the release of neurotransmitters in rat nerve terminals. An in vitro study under conditions that mimic anoxia, hypoglycemia, and ischemia. Stroke 27 (1996) 941-950
38. Small D.L., Morley P., and Buchan A.M. Biology of ischemic cerebral cell death. Prog. Cardiovasc. Dis. 42 (1999) 185-207
39. Sweeney M.I., Yager J.Y., Walz W., and Juurlink B.H. Cellular mechanisms involved in brain ischemia. Can. J. Physiol. Pharmacol. 73 (1995) 1525-1535
40. Teramoto N., Brading A.F., and Ito Y. Multiple effects of mefenamic acid on K(+) currents in smooth muscle cells from pig proximal urethra. Br. J. Pharmacol. 140 (2003) 1341-1350
41. Traystman R.J. Animal models of focal and global ischemia. ILAR J. 44 (2003) 85-95
42. In: Walz W. (Ed). Cerebral Ischemia: Molecular and Cellular Pathophysiology (1999), Humana Press
43. Wei L., Yu S.P., Gottron F., Snider B.J., Zipfel G.J., and Choi D.W. Potassium channel blockers attenuate hypoxia- and ischemia-induced neuronal death in vitro and in vivo. Stroke 34 (2003) 1281-1286
44. Zivin J.A. Clinical trials of neuroprotective therapies. Stroke 38 (2007) 791-793